Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) have been given an average recommendation of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $11.80.
CTMX has been the topic of several recent analyst reports. Zacks Investment Research lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 2nd. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of CytomX Therapeutics in a research report on Friday, March 4th. JPMorgan Chase & Co. dropped their price target on CytomX Therapeutics from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 2nd. StockNews.com raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Barclays raised CytomX Therapeutics from an “underweight” rating to an “overweight” rating and set a $7.00 target price on the stock in a research report on Tuesday, January 18th.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CTMX. Deutsche Bank AG boosted its position in CytomX Therapeutics by 6.2% in the 4th quarter. Deutsche Bank AG now owns 42,323 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 2,474 shares during the last quarter. Macquarie Group Ltd. boosted its position in shares of CytomX Therapeutics by 515.1% in the 3rd quarter. Macquarie Group Ltd. now owns 4,853 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 4,064 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in CytomX Therapeutics by 72.2% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 11,442 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 4,796 shares in the last quarter. Invesco Ltd. lifted its holdings in CytomX Therapeutics by 19.2% during the third quarter. Invesco Ltd. now owns 30,175 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 4,850 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in shares of CytomX Therapeutics by 429.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 11,619 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 9,426 shares during the period. Institutional investors own 92.79% of the company’s stock.
CytomX Therapeutics (NASDAQ:CTMX – Get Rating) last posted its quarterly earnings data on Tuesday, March 1st. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The company had revenue of $19.73 million during the quarter, compared to the consensus estimate of $29.21 million. CytomX Therapeutics had a negative net margin of 120.18% and a negative return on equity of 69.96%. During the same quarter last year, the business earned ($0.31) earnings per share. Research analysts anticipate that CytomX Therapeutics will post -1.6 earnings per share for the current fiscal year.
About CytomX Therapeutics (Get Rating)
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.
- Get a free copy of the StockNews.com research report on CytomX Therapeutics (CTMX)
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
- Iridium Communications Stock is Ready to Return to Orbit
- There’s An Institutional Floor In Keurig Dr. Pepper
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.